Amgen (AMGN) Other Non-Current Assets (2009 - 2026)
Amgen (AMGN) posted quarterly Other Non-Current Assets of $12.8 billion for Q1 2026, up 12.05% year-over-year from $11.4 billion in Q1 2025, and up 0.79% quarter-over-quarter from $12.7 billion in Q4 2025.
Amgen (AMGN) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Amgen's Other Non-Current Assets history runs 18 years deep, the most recent figure standing at $12.8 billion for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 12.05% year-over-year to $12.8 billion; the TTM figure through Mar 2026 stood at $12.8 billion (up 12.05% YoY), while the FY2025 annual figure was $12.7 billion, up 27.49% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $12.8 billion, up from $12.7 billion in the prior quarter.
- The five-year high for Other Non-Current Assets was $13.2 billion in Q3 2025, with the low at $5.9 billion in Q4 2022.
- The 5-year median for Other Non-Current Assets is $9.0 billion (2024), against an average of $9.2 billion.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets declined 9.58% in 2022, then soared 62.93% in 2023.
- Amgen's Other Non-Current Assets stood at $5.9 billion in 2022, then jumped by 62.93% to $9.6 billion in 2023, then gained by 3.32% to $9.9 billion in 2024, then gained by 27.49% to $12.7 billion in 2025, then climbed by 0.79% to $12.8 billion in 2026.
- Business Quant data shows AMGN's Other Non-Current Assets at $12.8 billion in Q1 2026, $12.7 billion in Q4 2025, and $13.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 14.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 10.73 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 19.60 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.93 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 12.98 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 4.75 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 9.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 3.56 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 5.50 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.98 Bn |
| Mar 31, 2026 | 12.76 Bn |
| Dec 31, 2025 | 12.66 Bn |
| Sep 30, 2025 | 13.22 Bn |
| Jun 30, 2025 | 11.02 Bn |
| Mar 31, 2025 | 11.39 Bn |
| Dec 31, 2024 | 9.93 Bn |
| Sep 30, 2024 | 10.38 Bn |
| Jun 30, 2024 | 8.82 Bn |
| Mar 31, 2024 | 9.01 Bn |
| Dec 31, 2023 | 9.61 Bn |
| Sep 30, 2023 | 7.84 Bn |
| Jun 30, 2023 | 7.19 Bn |
| Mar 31, 2023 | 7.63 Bn |
| Dec 31, 2022 | 5.90 Bn |
| Sep 30, 2022 | 6.34 Bn |
| Jun 30, 2022 | 6.02 Bn |
| Mar 31, 2022 | 6.07 Bn |
| Dec 31, 2021 | 6.52 Bn |
| Sep 30, 2021 | 6.31 Bn |